End of treatment ‐ heterozygous · people who smoke
It is very uncertain whether active NRT changes end of treatment ‐ heterozygous compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (very low certainty).
1 finding from 1 review
End of treatment ‐ homozygous minor · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous minor compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
Abstinence · people who smoke
Active NRT probably leads to higher 6‐Month abstinence compared with placebo ‐ NMR ‐ non‐Hispanic black and white (moderate certainty).
1 finding from 1 review
6‐Month abstinence ‐ slow NMR · people who smoke
Active NRT probably leads to higher 6‐Month abstinence ‐ slow NMR compared with placebo ‐ NMR ‐ non‐Hispanic black and white (moderate certainty).
1 finding from 1 review
6‐Month abstinence ‐ normal NMR · people who smoke
Active NRT showed no clear difference in 6‐Month abstinence ‐ normal NMR compared with placebo ‐ NMR ‐ non‐Hispanic black and white (low certainty).
1 finding from 1 review
End of treatment · people who smoke
Active NRT probably leads to higher end of treatment compared with placebo ‐ NMR ‐ non‐Hispanic black and white (moderate certainty).
1 finding from 1 review
End of treatment ‐ slow NMR · people who smoke
Active NRT probably leads to higher end of treatment ‐ slow NMR compared with placebo ‐ NMR ‐ non‐Hispanic black and white (moderate certainty).
1 finding from 1 review
End of treatment ‐ normal NMR · people who smoke
Active NRT showed no clear difference in end of treatment ‐ normal NMR compared with placebo ‐ NMR ‐ non‐Hispanic black and white (low certainty).
1 finding from 1 review
Abstinence at end of treatment ‐ homozygous minor · people who smoke
Active NRT may leads to higher abstinence at end of treatment ‐ homozygous minor compared with placebo ‐ rs1051730 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
End of treatment · people who smoke
Active NRT showed no clear difference in end of treatment compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (moderate certainty).
1 finding from 1 review
End of treatment ‐ homozygous major · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous major compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
End of treatment ‐ heterozygous · people who smoke
Active NRT leads to higher end of treatment ‐ heterozygous compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (high certainty).
1 finding from 1 review
End of treatment ‐ homozygous minor · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous minor compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
All reported adverse events · pressure ulcer prevention
1 finding from 1 review
Health‐related quality of life · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost‐effectiveness · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants developing a new pressure ulcer · pressure ulcer prevention
Reactive air surfaces may leads to lower proportion of participants developing a new pressure ulcer compared with foam surfaces (low certainty).
1 finding from 1 review
Time to pressure ulcer development · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Support surface associated patient comfort · pressure ulcer prevention
1 finding from 1 review
All‐cause mortality ‐ not reported · patients with oesophageal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found